Advertisement

Topics

Search Results for "Mylan Atovaquone And Proguanil 250mg 100mg Tablet"

11:49 EDT 24th March 2017 | BioPortfolio

Matching Channels

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

Genuine Macherey-Nagel Quantofix PeroxideTest Strips 1-100mg/L – Ref: 913 12

£15.00End Date: Friday Apr-14-2017 19:31:59 BSTBuy It Now for only: £15.00Buy It Now | Add to watch list Biotech365 : Genuine Macherey-Nagel Quantofix PeroxideTest Strips 1-100mg/L – Ref:...

BRIEF-ANI Pharmaceuticals launchs Vancomycin HCL 125mg, 250mg capsules

* ANI Pharmaceuticals Inc - launch of Vancomycin HCL 125mg, 250mg capsules in a fifty count bottle

FDA Accepts Mylan aBLA or Pegfilgrastim Biosimilar

Mylan N.V. and Biocon Ltd. have announced that the FDA has accepted Mylan's Biologics License Application for MYL-1401H, a proposed biosimilar to Amgen's Neulasta , for filing through the 351 ...

PERKIN ELMER TABLET AUTOSAMPLER FOR SPECTRUM ONE NTS TABLET AUTOSAMPLER SYSTEM

£375.00End Date: Sunday Feb-26-2017 11:49:53 GMTBuy It Now for only: £375.00Buy It Now | Add to watch list Biotech365 : PERKIN ELMER TABLET AUTOSAMPLER FOR SPECTRUM ONE NTS TABLET AUTOSAMPLER S...

Weak Outlook on Mylan

Mylan delivered 12.5% sales growth to $7.8 billion and -90% profit drop to $62.5 million. As observed, Mylan had an overall 40.6% growth in operating expenses.

A look at a High Market Cap Stock: Mylan N.V., MYL

Mylan N.V., MYL is in the exchange NASDAQ and its industry is Drugs - Generic in the sector of Healthcare. Based in USA, Mylan N.V., MYL has a market cap of 19675.89.

Mylan N.V. (MYL) Downgraded to "Strong Sell" at Zacks Investment Research

According to Zacks, "There seems to be no end to Mylan's woes. Recently, 20 U.S. states filed a federal lawsuit against several generic drug makers including Mylan.

Mylan N.V. (MYL) Lowered to "Strong Sell" at Zacks Investment Research

According to Zacks, "There seems to be no end to Mylan's woes. Recently, 20 U.S. states filed a federal lawsuit against several generic drug makers including Mylan.

Matching PubMed Articles

Modulation of microenvironmental pH for dual release and reduced in vivo gastrointestinal bleeding of aceclofenac using hydroxypropyl methylcellulose-based bilayered matrix tablet.

This study was designed to develop a once-daily controlled-release matrix tablet of aceclofenac 200mg (AFC-CR) with dual release characteristics and to investigate the role of an alkalizer in enhancin...

Microstructure of Tablet-Pharmaceutical Significance, Assessment, and Engineering.

To summarize the microstructure - property relationship of pharmaceutical tablets and approaches to improve tablet properties through tablet microstructure engineering.

Investigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based interactivity calculations.

The widespread introduction of artemisinin-based combination therapy has contributed to recent reductions in malaria mortality. Combination therapies have a range of advantages, including synergism, t...

Multispectral UV imaging for determination of the tablet coating thickness.

The applicability of off-line multispectral ultraviolet (UV) imaging in combination with multivariate data analysis was investigated to determine the coating thickness and its distribution on the tabl...

HIV update: Which single-tablet regimens, and when.

With the approval of single-tablet regimens that contain 3 or 4 drugs, many patients take just one pill a day. So what are the options and what's on the horizon?

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement